Serum matrix metallopeptidase-9 levels in infantile epileptic spasms syndrome of unknown etiology
- PMID: 39342693
- DOI: 10.1016/j.eplepsyres.2024.107454
Serum matrix metallopeptidase-9 levels in infantile epileptic spasms syndrome of unknown etiology
Abstract
Purpose: Epileptic spasms are the primary symptom of infantile epileptic spasms syndrome (IESS); however, their direct impact on blood-brain barrier (BBB) function is unknown. Matrix metallopeptidase-9 (MMP-9), degrades type IV collagen, a key component of the blood-brain barrier, while tissue inhibitor of metalloproteinase-1 (TIMP-1) suppresses its activity, protecting BBB integrity. This study aimed to assess serum MMP-9 and TIMP-1 levels in patients with IESS of unknown etiology.
Methods: We prospectively assessed serum MMP-9 and TIMP-1 levels prior to administering vigabatrin or adrenocorticotropic hormone therapy in patients with IESS of unknown etiology at Saitama Children's Medical Center between February 2012 and December 2023. We compared these biomarkers between patients with epileptic spasms and age-matched controls and performed a curve regression analysis between the biomarkers and the frequency of epileptic spasms. Additionally, we assessed whether MMP-9 and TIMP-1 levels were diagnostic predictors of IESS.
Results: This study included 22 patients with IESS (11 males) and 12 controls. Serum MMP-9 and MMP-9/TIMP-1 ratios were higher in patients with IESS than in controls (p < 0.001 and p = 0.002, respectively). A high frequency of epileptic spasms also led to higher serum MMP-9 levels (y = 0.0871x2 + 0.195x + 195.15, R² = 0.77, p < 0.001). Using MMP >188 ng/mL as the cutoff level, the sensitivity for diagnosing IESS was 95.5 %, the specificity was 75.0 %, the positive likelihood ratio was 3.82 (95 % confidence interval (CI) 1.43-10.22), and the relative risk was 8.75 (95 % CI 1.36-56.5).
Conclusion: Patients with IESS had elevated serum MMP-9 levels, suggesting an association between epileptic spasms and blood-brain barrier dysfunction. MMP-9 level measurement may be useful for diagnosing suspected patients.
Keywords: biomarker; blood–brain barrier; diagnosis; epilepsy; matrix metallopeptidase-9, predictor.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Shin-ichiro Hamano received funding from Daiichi Sankyo Co. Ltd., UCB Japan Co. Ltd., and Eisai Co. Ltd. Kenjiro Kikuchi received research funding from Syneos Health Clinical Co. Ltd. and Janssen Pharmaceutical K.K. The other authors declare no conflicts of interest.
Similar articles
-
Serum matrix metallopeptidase-9 and tissue inhibitor of metalloproteinase-1 levels may predict response to adrenocorticotropic hormone therapy in patients with infantile spasms.Brain Dev. 2022 Feb;44(2):114-121. doi: 10.1016/j.braindev.2021.08.003. Epub 2021 Aug 22. Brain Dev. 2022. PMID: 34429218
-
Adrenocorticotropic hormone therapy alters Q-albumin ratios in patients with infantile epileptic spasms syndrome of unknown etiology.J Neurol Sci. 2024 Oct 15;465:123187. doi: 10.1016/j.jns.2024.123187. Epub 2024 Aug 16. J Neurol Sci. 2024. PMID: 39173325
-
Epileptic spasms relapse is associated with response latency but not conventional attributes of post-treatment EEG.Epilepsia Open. 2024 Jun;9(3):1034-1041. doi: 10.1002/epi4.12931. Epub 2024 Apr 8. Epilepsia Open. 2024. PMID: 38588009 Free PMC article.
-
Genetic Advancements in Infantile Epileptic Spasms Syndrome and Opportunities for Precision Medicine.Genes (Basel). 2024 Feb 21;15(3):266. doi: 10.3390/genes15030266. Genes (Basel). 2024. PMID: 38540325 Free PMC article. Review.
-
Mechanisms of infantile epileptic spasms syndrome: What have we learned from animal models?Epilepsia. 2024 Feb;65(2):266-280. doi: 10.1111/epi.17841. Epub 2023 Dec 18. Epilepsia. 2024. PMID: 38036453 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous